A steep rise in the adoption of combination drugs has happened to spur the surge to such extent. Also, the desired results in controlling HIV & related ailments have augmented the use of this medication.
Allied Market Research published a report, titled, “HIV Drug Market by Medication class [multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase stand transfer inhibitors] – Global Opportunity Analysis and Industry Forecast, 2014-2022.” According to the report, the global HIV drug market is anticipated to bring in $26,458 million by 2022, airing a CAGR of 3.7% throughout the forecast period 2016-2022.
Get Sample Report: https://www.alliedmarketresearch.com/request-sample/1867
The report includes an in-depth analysis of key market segments, research methodology, market scope, market size & forecast, market dynamics, market share analysis, product pipeline analysis, key growth factors & opportunities, operating business segments, business performance and key strategic moves as well as developments.
The multi class combination drugs sector contributed to more than one-third of the total market share in the year 2015. A steep rise in the adoption of combination drugs has happened to spur the surge to such extent. Also, the desired results in controlling HIV & related ailments have augmented the use of this medication. Simultaneously, the much-needed ease in consuming the drugs has egged on the cause too. At the same time, rise in the number of HIV-ridden patients has swelled up the need for top-end treatment. Prezista and Atripla are two effective drugs used in the treatment of HIV.
Again, the market is analyzed across various regions including North America, Asia-Pacific, Europe, and Latin America, Middle East and Africa (LAMEA). North America happened to garner the highest revenue in 2015. The rising awareness about healthcare in the province, advanced diagnosis & treatment, high-end healthcare system and preemptive initiatives by Government to check the spread of the disease in North American countries have accounted for the growth. Merck & Co, Novartis, GlaxoSmithKline and Gilead are some of the key players in the HIV drugs market in North America. Nevertheless, Asia-pacific region is expected to air up the highest CAGR of 6.3% throughout the forecast period. When the number of HIV patients has come across a significant rise, the unattained medical needs in the region have also been achieved in the past few years. Moreover, a number of growth opportunities have hit the scenario as well. On top of that, the incessant support from the leading players has propelled the growth of HIV drugs market in the Asia-pacific region.
The major market players analyzed in the report include Boehringer Ingelheim International GmbH, AbbVie, Cipla Limited, F. Hoffmann-La Roche Ltd., Merck & Co., ViiV Healthcare, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, and Gilead Sciences. Their exclusive market strategy and dynamics have helped them retain their stand in the market. Also, their competitive outlook towards the marked has been right behind their success story.
